What orforglipron is
Orforglipron, sold by Eli Lilly as Foundayo, is a GLP-1 (glucagon-like peptide-1) receptor agonist taken as a once-daily tablet. It was not the first GLP-1 pill approved for weight management — the Wegovy pill, an oral form of semaglutide, launched in January 2026. What makes orforglipron different is that it is a non-peptide small molecule rather than a peptide, and that is what frees it from the empty-stomach dosing rules oral semaglutide requires.
Lilly states it is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep it off. It should not be used with other GLP-1 receptor agonist medicines, and it has not been established as safe and effective in children.
Why “no food or water restrictions” matters
Lilly describes Foundayo as the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. The comparison that matters is the Wegovy pill, which launched in January 2026: oral semaglutide must be taken in the morning on an empty stomach with no more than 4 oz of plain water, followed by a wait of at least 30 minutes before eating, drinking anything else, or taking other oral medications. That is a peptide-versus-non-peptide difference rather than an old-versus-new one — and for anyone who has abandoned a medication because the routine was unworkable, it is the headline feature.
What the trials showed
Lilly publishes results from two 72-week studies. These are the figures from the company's own patient materials.
Adults without diabetes, 72 weeks
| Dose | Average weight loss | Average starting weight |
|---|---|---|
| 5.5 mg | 7.4% (17.2 lbs) | 227 lbs |
| 9 mg | 8.3% (18.9 lbs) | 225 lbs |
| 17.2 mg | 11.1% (24.9 lbs) | 227 lbs |
| Placebo | 2.1% (5.3 lbs) | 229 lbs |
Adults with type 2 diabetes, 72 weeks
| Dose | Average weight loss | Average starting weight |
|---|---|---|
| 5.5 mg | 5.1% (11.7 lbs) | 226 lbs |
| 9 mg | 7% (15.9 lbs) | 226 lbs |
| 17.2 mg | 9.6% (21.2 lbs) | 220 lbs |
| Placebo | 2.5% (5.9 lbs) | 223 lbs |
Two patterns are worth noting. The response is clearly dose-dependent — more than a percentage point of body weight separates each step up. And, as with every GLP-1 studied in both populations, people with type 2 diabetes lost less on the same dose than people without it. That is a consistent finding across this drug class, not a quirk of these trials.
How it compares to the injectables
This is the question that should drive the decision, and the honest answer is that orforglipron trades efficacy for convenience.
| Medication | Form | Avg weight loss at top dose | Trial |
|---|---|---|---|
| Tirzepatide (Zepbound) | Weekly injection | ~20.9% | SURMOUNT-1, 72 weeks |
| Semaglutide (Wegovy) | Weekly injection | ~14.9% | STEP 1, 68 weeks |
| Orforglipron (Foundayo) | Daily tablet | 11.1% | 72-week study, no diabetes |
Read this table carefully
These are separate trials with different protocols, populations, and durations — not head-to-head comparisons. Cross-trial percentages are indicative, not decisive, and anyone presenting them as a definitive ranking is overstating what the evidence supports. What you can reasonably take from it is that the oral option is unlikely to match the top injectable on average weight loss, and that individual responses vary widely regardless of which column you are in.
Dosing
Lilly Medical states the titration schedule begins at 0.8 mg once daily, increasing to 2.5 mg once daily after at least 30 days, and then to 5.5 mg once daily after at least a further 30 days. The maximum dose is 17.2 mg once daily, and the product comes in six tablet strengths spanning 0.8 mg to 17.2 mg.
Practical rules that appear consistently across the prescribing information:
- Take it once daily, with or without food, at any time of day.
- Swallow tablets whole — do not break, crush, or chew them.
- Do not take more than one tablet per day.
- The maximum dose drops to 9 mg once daily if you are also taking a strong CYP3A4 inhibitor, and strong CYP3A4 inducers should be avoided.
That last point deserves emphasis, because it is easy to miss. A common interacting medication can cap you at roughly half the maximum dose — and since the response is dose-dependent, that materially changes what you should expect. Give your prescriber a complete list of everything you take, including supplements.
Warnings and side effects
Foundayo carries the same thyroid tumor warning as other medicines in this class. Lilly states that in studies with rats, Foundayo and medicines that work like it caused thyroid tumors, including thyroid cancer, and that it is not known whether Foundayo causes thyroid tumors or medullary thyroid carcinoma (MTC) in people.
Do not take Foundayo if
- • You or any family member have ever had medullary thyroid carcinoma (MTC)
- • You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Tell your healthcare provider if you develop a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These can be symptoms of thyroid cancer.
Foundayo should not be used with other orforglipron-containing products or with any other GLP-1 receptor agonist medicine. If you are already on an injectable GLP-1, switching is a decision for your prescriber rather than something to manage yourself.
Gastrointestinal effects dominate the side effect profile across this drug class — nausea, diarrhea, constipation, and vomiting, typically most pronounced during dose increases. Our GLP-1 side effects guide covers the class in more detail, and the prescribing information supplied with your prescription is the authoritative source for this specific product.
What it costs
LillyDirect lists Foundayo starting at $149 through self-pay. As with every manufacturer offer in this category, that figure is dose-limited and dated rather than a flat price.
GoodRx Care publishes the structure in more detail: its Foundayo offer applies only to the 0.8 mg dose, with 2.5 mg increasing to $199 after December 31, 2026, and higher doses at $299 per month — plus a $39/month membership that does not include medication cost.
Budget for the dose you will end up on
The advertised price attaches to the 0.8 mg starting dose. Since the trial data shows the response is strongly dose-dependent, most people aiming for meaningful weight loss will titrate well past that — and into the $299/month tier. This is the same pattern we see with Zepbound self-pay pricing, and it is the single most common way people underestimate what a course of treatment costs.
Several telehealth platforms already list Foundayo, including LifeMD, Found, and Ivím Health.
Who it may suit
Worth asking about if you:
- •Will not or cannot use a weekly injection
- •Have found cold-chain shipping and refrigeration impractical
- •Struggled with the empty-stomach routine of older oral GLP-1 products
- •Want a GLP-1 with a simpler daily habit, and accept a smaller average effect
- •Have a needle phobia that has kept you from starting treatment at all
Probably not if you:
- •Are optimising for the largest average weight loss
- •Are already doing well on an injectable GLP-1
- •Take a strong CYP3A4 inhibitor that would cap your dose at 9 mg
- •Have a personal or family history of MTC, or have MEN 2
- •Would struggle with a daily dosing habit more than a weekly one
The bottom line
Orforglipron is a genuine addition to the toolkit rather than a replacement for what already exists. A once-daily tablet with no food or water restrictions removes several real barriers — needles, refrigeration, cold-chain shipping, and the empty-stomach routine the Wegovy pill requires — and for some people those barriers were the reason they never started.
It also produced less average weight loss in trials than either injectable. If your priority is the largest expected effect, the injectables still lead. If your priority is a medication you will actually take every day for years, the calculation may look different. That is a genuine trade-off, and it is your prescriber's job to help you weigh it against your own history.
Frequently Asked Questions
Is Foundayo (orforglipron) FDA approved?+
Yes. Foundayo was first approved on April 1, 2026. It is approved for use in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight in adults with obesity, or adults with overweight who also have weight-related medical problems. It is not known whether it is safe and effective in children.
How much weight did people lose in the trials?+
Lilly publishes results from a 72-week study of adults without diabetes: average weight loss was 7.4% (17.2 lbs) at 5.5 mg, 8.3% (18.9 lbs) at 9 mg, and 11.1% (24.9 lbs) at 17.2 mg, against 2.1% (5.3 lbs) for placebo. Average starting weights were around 225-229 lbs. In a separate 72-week study of adults with type 2 diabetes, average weight loss was 5.1% at 5.5 mg, 7% at 9 mg, and 9.6% at 17.2 mg, against 2.5% for placebo.
How does it compare to Wegovy and Zepbound?+
On average weight loss, it is lower. Lilly reports 11.1% at the top orforglipron dose over 72 weeks. Semaglutide produced about 14.9% at 68 weeks in STEP 1, and tirzepatide about 20.9% at the top dose in SURMOUNT-1. These are separate trials with different populations and are not head-to-head comparisons, so treat the gap as approximate — but the direction is consistent. What orforglipron offers instead is a daily tablet with no injections.
How is Foundayo dosed?+
Lilly Medical states the starting dose is 0.8 mg once daily, increasing to 2.5 mg once daily after at least 30 days, then to 5.5 mg once daily after at least a further 30 days. The maximum dose is 17.2 mg once daily, and it comes in six tablet strengths ranging from 0.8 mg to 17.2 mg. Swallow tablets whole — do not break, crush, or chew them — and take no more than one tablet per day.
Do I have to take it on an empty stomach?+
No. Lilly describes Foundayo as the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions, and it can be taken with or without food. The contrast is the Wegovy pill, which must be taken in the morning on an empty stomach with no more than 4 oz of plain water, then a 30-minute wait before eating, drinking anything else, or taking other oral medications.
What are the main warnings?+
Foundayo carries the GLP-1 class warning about thyroid tumors. In studies with rats, Foundayo and medicines that work like it caused thyroid tumors, including thyroid cancer; it is not known whether it causes thyroid tumors or medullary thyroid carcinoma (MTC) in people. Do not take Foundayo if you or any family member have ever had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider about any lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath.
Can I take it alongside another GLP-1?+
No. Lilly states Foundayo should not be used with other orforglipron-containing products or with any other GLP-1 receptor agonist medicine. If you are switching from an injectable GLP-1, that transition is a conversation for your prescriber.
Are there drug interactions to know about?+
Yes. The maximum dose of Foundayo is 9 mg once daily when used with a strong CYP3A4 inhibitor, and strong CYP3A4 inducers should be avoided. Give your prescriber a complete list of your medications and supplements, since this interaction restricts the dose you can reach.
What does Foundayo cost?+
LillyDirect lists Foundayo starting at $149 through self-pay. GoodRx Care states its Foundayo offer applies only to the 0.8 mg dose, with 2.5 mg increasing to $199 after December 31, 2026 and higher doses at $299/month, on top of a $39/month membership. As with every manufacturer offer in this category, the introductory price is dose-limited and dated.
Sources
- Foundayo (Lilly) — indication, approval status, 72-week trial results for both populations, boxed warning language, dosing rules
- Lilly Medical — approved titration schedule (0.8 mg → 2.5 mg → 5.5 mg, minimum 30 days between steps); maximum 9 mg daily with a strong CYP3A4 inhibitor
- FDA — FOUNDAYO (orforglipron) tablets prescribing information, CYP3A4 dosing restriction
- GoodRx Care — Foundayo dose-tier pricing and offer end dates
- Comparator figures: STEP 1 (semaglutide) and SURMOUNT-1 (tirzepatide) published trial results, cited on our semaglutide and tirzepatide guides. Verified August 5, 2026.
🇺🇸Medical Disclaimer
Your health, your doctor. This guide summarises published information about a prescription medication. It is not medical advice, and we are researchers rather than clinicians. Orforglipron is not appropriate for everyone and carries a warning about thyroid tumors. The prescribing information supplied with your medication, and the clinician managing your care, are the authoritative sources. Individual responses vary significantly. Verified August 5, 2026.